Monthly Archives: February 2012

Attorneys Andres Alonso and David Krangle Announce that Alonso Krangle LLP has Filed Suit on Behalf of a Wisconsin Woman who was Diagnosed with a Right Femur Fracture after Using the Bisphosphonate, Fosamax, for over Five Years Melville, NY (PRWEB) February 20, 2012 The law firm Alonso Krangle LLP, a national law firm focused on fighting for the rights of victims due to drug side effects, announce their firm has filed a Fosamax lawsuit on behalf of Judy Kinning, a resident of Wisconsin, who was diagnosed with a right femur fracture after using the oral bisphosphonate, Fosamax, for over five years. Ms. Kinning’s Fosamax lawsuit was filed on January 30, 2012, in the Superior Court of New Jersey, Atlantic County Division, and names Merck Sharp & Dohme Corp. f/k/a Merck & Company, Inc. and Teva Pharmaceuticals as Defendants (Docket No. ATL-L-000795-2012-MT) The lawyers at the firm Alonso Krangle LLP are currently offering free Fosamax lawsuit evaluations to anyone who experienced a femur fracture that may be due to Fosamax side effects. To discuss a potential Fosamax lawsuit claim with an experienced and compassionate Fosamax side effects lawyer, please contact Alonso Krangle LLP at 1-800-403-6191 or visit our website, http://www.FightForVictims.com According … Continue reading →

Washington, Feb 20 (IANS) Drugs for Alzheimer's disease currently undergoing clinical trials may have adverse side-effects, warns a new study. The drugs could act like a bad electrician, causing neurons (nerve cells) to be miswired and tripping their ability to message the brain, suggests the study. "Let's proceed with caution," said Robert Vassar, professor of cell and molecular biology at Feinberg School of Medicine, who led the study conducted on mice, the journal Molecular Neurodegeneration reports. "We have to keep our eyes open for potential side effects of these drugs." Ironically, the drugs could impair memory, said Vassar, according to a Feinberg statement. The drugs are designed to inhibit BACE1, the enzyme Vassar originally discovered that promotes the development of the clumps of plaque that characterise Alzheimer's. BACE1 acts as a molecular scissors, cutting up and releasing proteins that form the plaques. Thus, drug developers believed blocking the enzyme might slow the disease. But in Vassar's new study, he found BACE1 also has a critical role as the brain's electrician. The enzyme maps out the location of axons, the wires that connect neurons to the brain and the rest of the nervous system. Working with mice from which BACE1 was … Continue reading →

February 20, 2012 A weight-loss drug currently under a second review from the Food and Drug Administration (FDA) is causing concerns that it may be responsible for birth defects and heart problems, according to documents released by the agency on Friday. The drug, developed by Vivus, was rejected by the agency in 2010, largely because of those risks. A committee of outside advisers to the FDA will meet this week to reconsider whether the drug, called Qnexa, should move forward in the approval process, reports Andrew Pollack for the NY Times. Obesity specialists and patient advocates agree there is a huge need for obesity drugs to bridge a treatment gap between diet and exercise, which do not work for many people, and bariatric surgery, which is expensive and not suitable for those with specialized medical conditions. The FDA, however, has been cautious with approving diet drugs, in part because with two-thirds of American adults overweight or obese, such drugs might be used for a long time by millions of people. There is an FDA Advisory Panel meeting this month that is tasked with combing through 2-years’ worth of clinical data. When Qnexa was last reviewed, the Agency only had 1-year’s … Continue reading →

Public release date: 20-Feb-2012 [ | E-mail | Share ] Contact: Katarina Sternudd katarina.sternudd@ki.se 46-852-483-895 Karolinska Institutet A team of researchers at Karolinska Institutet in Sweden has generated a map over the effects of small drug-like molecules on PARP1 and other similar proteins in the body. This map may explain the mechanism behind putative side effects of the so-called PARP inhibitors, and can play an important role in the development of novel tailor-made cancer drugs. The study is presented in the journal Nature Biotechnology, and will hopefully contribute to new cancer therapies with fewer detrimental side effects. PARP1 is a protein with enzymatic activity that governs repair of DNA damage in our cells. In the past decade, PARP1 has been in the focus for a large number of industrial drug development projects, primarily targeting breast and ovarian cancers. More than 50 clinical studies have been initiated around the world. In the current study, the researchers at Karolinska Institutet have tested the effects of small drug-like molecules ? inhibitors ? on PARP1 and other enzymes of the same class. The effects of 180 substances on 13 different human PARP enzymes were studied. Many of the drugs that are currently being tested … Continue reading →